Cybin (CYBN) announced a partnership with closely held Segal Trials to support the multinational pivotal phase 3 program for evaluating CYB003 as a treatment for major depressive disorder.
The phase 3 program plans to enroll 550 patients at more 40 clinical sites in the US and Europe, Cybin said Wednesday in a statement.
Segal Trials, the first program member, has six research sites in South Florida with an emphasis on psychiatry, neurology, addiction and psychedelics, Cybin said.
Shares of Cybin rose 4.8% in recent Wednesday trading.
Price: 9.25, Change: +0.42, Percent Change: +4.78
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments